Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a mushroom boost liver recovery after cancer treatment?

NCT ID NCT07178093

Symptom relief Sponsor: Taichung Tzu Chi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a mushroom extract called Antrodia cinnamomea can help liver cancer patients recover liver function and improve quality of life after a procedure called transcatheter arterial chemoembolization (TACE). Sixty adults with liver cancer will take either the supplement or a placebo for 11 days around the procedure. Researchers will measure liver enzyme levels and quality of life over 28 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Antrodia cinnamomea (a mushroom extract)
What this could lead to
If it works, this could show that Antrodia cinnamomea helps liver cancer patients recover liver function faster and feel better after a standard procedure called TACE.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. The supplement is not a treatment for cancer itself, and its benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sign the informed consent form * Aged between 20 and 80 * Child-Pugh score class A, B * Serum bilirubin level ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal Exclusion Criteria: * Unwillingness to sign the informed consent form * Child-Pugh score class C * Patients with main portal vein thrombosis * Patients with diffuse liver tumors * Those who are allergic to the contrast medium * Those with abnormal coagulation function * Those with severe dysfunction of brain, heart and lung * Patients with severe renal dysfunction (except those receiving renal dialysis) * Unable to cooperate * Those with uncontrolled arrhythmia and unstable blood pressure * Some patients with abnormal thyroid function * Any other contraindications such as active gastrointestinal bleeding, refractory ascites, or severe portal hypertension * Pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Transarterial chemoembolization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taichung Tzu-Chi Hospital

    RECRUITING

    Taichung, Taiwan, 406, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.